Study on the Effectiveness and Safety of Navepegritide for Adolescents with Achondroplasia

2 1

What is this study about?

This clinical trial is focused on studying achondroplasia, a condition that affects bone growth, leading to shorter stature. The study will evaluate a treatment called TransCon CNP, which is a solution for injection. This treatment involves a special protein called c-type natriuretic peptide that is linked to a carrier molecule to help it work effectively in the body. The purpose of the study is to assess how well this treatment works in promoting growth in adolescents aged 12 to under 18 years who have achondroplasia.

Participants in the study will receive weekly injections of either TransCon CNP or a placebo for a period of 52 weeks. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The main goal is to see if the treatment can improve growth over the course of the study.

Throughout the study, participants will be monitored for any changes in their height and overall health. The study aims to provide valuable information on the safety and effectiveness of TransCon CNP in treating achondroplasia, potentially offering a new option for managing this condition in adolescents.

1 joining the study

Upon joining the study, informed consent or assent is required. This involves signing a document that explains the study and confirms understanding and agreement to participate. For those under the legal age of consent, a parent or legal guardian must also provide consent.

Participants must be between 12 and less than 18 years old, with a clinical diagnosis of achondroplasia confirmed by genetic testing.

2 randomization and initial assessment

Participants are randomly assigned to receive either the study medication, TransCon CNP, or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

An initial assessment is conducted, including a review of medical history and a physical examination. A historical height measurement from medical records, taken between 6 to 15 months prior to screening, is required.

3 treatment phase

Participants receive a subcutaneous injection of the assigned treatment once a week for 52 weeks. The injection is administered under the skin.

Parents or legal guardians are responsible for administering the weekly injections and following the study protocol.

4 monitoring and follow-up

Throughout the study, regular monitoring is conducted to assess the participant’s growth and overall health. This includes measuring height and evaluating any changes from the baseline height Z-score.

The primary goal is to evaluate the average growth velocity (AGV) at week 52.

5 completion of the study

At the end of the 52-week treatment period, a final assessment is conducted to evaluate the efficacy and safety of the treatment.

The study is estimated to conclude by January 1, 2027.

Who Can Join the Study?

The participant, or their parent(s) or legal guardian(s), must provide a written, signed agreement to join the study. This is called informed consent. If the participant is too young to give consent, they will need to give a written agreement called assent. When they reach the legal age, they will need to provide their own written consent.
The participant must be a boy or girl aged between 12 and less than 18 years old at the time they are randomly chosen to join the study.
The participant must have a clinical diagnosis of achondroplasia, which is a condition affecting bone growth, confirmed by a genetic test. Previous test results can be used as proof.
The participant’s parent(s) or legal guardian(s) must be willing and able to give weekly injections under the skin, known as subcutaneous (SC) injections, and follow the study’s rules.
There must be at least one past measurement of the participant’s height while standing, available from medical records. This measurement should have been taken between 6 to 15 months before the screening for the study.

Who Cannot Join the Study?

Children and adolescents who do not have Achondroplasia, a condition affecting bone growth, cannot participate.
Individuals outside the specified age range for the study cannot participate.
Participants who are not available for the entire duration of the study cannot participate.
Those with other medical conditions that might interfere with the study cannot participate.
Individuals who are currently participating in another clinical trial cannot participate.
Participants who have had recent surgery or plan to have surgery during the study cannot participate.
Those who are unable to comply with the study procedures cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Hopital Necker Enfants Malades	Paris	France

Other Sites

Site Name	City	Country	Status
Rigshospitalet	Copenhagen	Denmark
Children’s Health Ireland	Dublin	Ireland

Trial status

Country	Status	Recruitment Start
Denmark	Recruiting	01.11.2024
France	Recruiting	01.11.2024
Ireland	Recruiting	01.11.2024

Trial locations

Navepegritide is a medication being studied for its potential to help with growth in adolescents with achondroplasia. Achondroplasia is a condition that affects bone growth, leading to shorter stature. This medication is given as an injection under the skin once a week. The trial aims to see if it can safely and effectively improve growth over a period of 52 weeks.

Achondroplasia – Achondroplasia is a genetic disorder that affects bone growth, leading to dwarfism. It is characterized by an average-sized trunk, short arms and legs, and a slightly enlarged head with a prominent forehead. The condition is caused by a mutation in the FGFR3 gene, which affects the conversion of cartilage to bone, particularly in the long bones. Children with achondroplasia typically have normal intelligence and life expectancy. As they grow, they may experience delayed motor skills and may require assistance with certain physical activities. The condition is present from birth and remains throughout life.

Trial ID:

2024-514208-15-00

Protocol code:

ASND0045

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Navepegritide for Adolescents with Achondroplasia

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?